CLOSEOUT LETTER
Prescription Lab Compounding Pharmacy
- Recipient:
- Prescription Lab Compounding Pharmacy
United States
- Issuing Office:
United States
| |
Division of Pharmaceutical Quality Operations IV 19701 Fairchild Road Los Angeles, CA 92612 |
VIA UNITED PARCEL SERVICE
SIGNATURE REQUIRED
June 27, 2017
David A. Nicoletti, R.Ph., President
MFP Limited, dba Prescription Lab Compounding Pharmacy
6586 E. Grant Road
Tucson, AZ 85715
Dear Mr. Nicoletti:
The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (WL#07-17) dated November 16, 2016. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
CDR Steven E. Porter, Jr.
Director, Division of Pharmaceutical Quality Operations IV